first booster dose - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.12 [0.06, 0.24]< 10%1 study (-/1)100.0 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.12 [0.06, 0.24]< 10%1 study (-/1)100.0 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.23 [0.15, 0.35]< 198%7 studies (-/7)100.0 %NAnot evaluable important-
hospitalization 0.15 [0.12, 0.18]< 10%5 studies (-/5)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.27 [0.21, 0.34]< 195%4 studies (-/4)100.0 %NAnot evaluable important-
ICU admission 0.07 [0.02, 0.25]< 10%1 study (-/1)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.